Ralliant (NYSE:RAL) Updates FY 2026 Earnings Guidance

Ralliant (NYSE:RAL) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.220-2.420 for the period, compared to the consensus estimate of 2.710. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.1 billion. Ralliant also updated its Q1 2026 guidance to 0.460-0.520 EPS.

Ralliant Stock Performance

NYSE RAL traded up $1.38 during trading hours on Wednesday, hitting $56.11. The company had a trading volume of 2,847,355 shares, compared to its average volume of 1,384,394. The company has a quick ratio of 1.03, a current ratio of 1.49 and a debt-to-equity ratio of 0.39. The firm has a market cap of $6.33 billion and a P/E ratio of 44.18. Ralliant has a fifty-two week low of $40.70 and a fifty-two week high of $57.02. The business has a fifty day simple moving average of $51.92 and a 200-day simple moving average of $46.83.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Wednesday, February 4th. The company reported ($12.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.67 by ($12.77). Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Ralliant’s payout ratio is currently 15.75%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Royal Bank Of Canada lifted their target price on Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research note on Friday, November 7th. Barclays increased their target price on shares of Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, January 7th. Citigroup upgraded shares of Ralliant from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $53.00 to $61.00 in a research report on Monday, December 8th. Oppenheimer increased their price objective on shares of Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Ralliant has an average rating of “Moderate Buy” and a consensus target price of $58.00.

Institutional Trading of Ralliant

Hedge funds have recently added to or reduced their stakes in the business. Quarry LP acquired a new stake in Ralliant during the third quarter worth approximately $64,000. Resources Management Corp CT ADV grew its stake in shares of Ralliant by 84.6% in the third quarter. Resources Management Corp CT ADV now owns 2,575 shares of the company’s stock valued at $113,000 after acquiring an additional 1,180 shares in the last quarter. Brown Brothers Harriman & Co. raised its stake in Ralliant by 167.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,958 shares of the company’s stock worth $129,000 after purchasing an additional 1,850 shares in the last quarter. Parallel Advisors LLC bought a new position in shares of Ralliant during the third quarter worth approximately $61,000. Finally, Osaic Holdings Inc. acquired a new position in Ralliant in the 2nd quarter valued at $66,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.